Registrati per interagire nei nostri forum attivi per discutere con investitori con idee simili.
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's product candidate includes ZYNLONTA, camidanlumab tesirine, ADCT-602,... ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's product candidate includes ZYNLONTA, camidanlumab tesirine, ADCT-602, ADCT-601, ADCT-901, ADCT-701 and ADCT-212. Mostra di più
| Periodo † | Var | Var % | Apert. | Max | Min | Med. Vol. Giorn. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.305 | -17.1348314607 | 1.78 | 1.8393 | 1.4101 | 335143 | 1.62369805 | CS |
| 4 | -0.105 | -6.64556962025 | 1.58 | 1.91 | 1.4101 | 345440 | 1.72641543 | CS |
| 12 | -0.545 | -26.9801980198 | 2.02 | 2.195 | 1.39 | 455563 | 1.7259779 | CS |
| 26 | -1.595 | -51.9543973941 | 3.07 | 3.49 | 1.39 | 647173 | 2.31739783 | CS |
| 52 | -2.955 | -66.7042889391 | 4.43 | 5.38 | 1.39 | 586045 | 2.92585695 | CS |
| 156 | -11.795 | -88.8847023361 | 13.27 | 16.04 | 0.359908 | 539172 | 3.27392219 | CS |
| 260 | -28.525 | -95.0833333333 | 30 | 56.5899 | 0.359908 | 422857 | 8.71722721 | CS |
Assistenza: support@advfn.it
Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni
Caratteristiche principali
Premium
